drugset / Trial / NCT05647213
Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to test the safety of lab-grown heart cells made from stem cells in subjects with congenital heart disease. The main questions it aims to answer are: * Is this product safe to deliver to humans * Is the conduct of this trial feasible Participants will be asked to: * Agree to testing and monitoring before and after product administration * Receive investigational product * Agree to lifelong follow-up Researchers will compare subjects from the same pool to see if there is a difference between treated and untreated subjects.
Timeline
- Start
- 2023-02-03
- Primary completion
- 2027-09
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iPSC-CL | Cell therapy | — | — |